BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.

ABSTRACT:

Background

Obesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an "obesity paradox" in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies.

Research question

Does BMI modify treatment effectiveness in PAH?

Study design and methods

Using individual participant data, a meta-analysis was conducted of phase III, randomized, placebo-controlled trials of treatments for PAH submitted for approval to the U.S. Food and Drug Administration from 2000 to 2015. Primary outcomes were change in 6-min walk distance (6MWD) and World Health Organization (WHO) functional class.

Results

A total of 5,440 participants from 17 trials

SUBMITTER: McCarthy BE 

PROVIDER: S-EPMC9470735 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature